NASDAQ:

phar

Pharming Group N.V. – ADS, each representing 10 ordinary shares

Country

Sector

Healthcare

Industry

Biotechnology

Profile

Technical / signals

News & Publications

Profile

Technical / signals

News & Publications

About Pharming Group N.V. - ADS, each representing 10 ordinary shares

Overview

Questions & Answers

How do I buy Twitter (TWTR) stock?

Valuation Measures

P/E Current

N/A

P/E Ratio (w/ extraordinary items)

N/A

P/E Ratio (w/o extraordinary items)

N/A

Price to Sales Ratio

6.79

Price to Book Ratio

4.73

Price to Cash Flow Ratio

42.20

Enterprise Value to EBITDA

43.84

Enterprise Value to Sales

7.06

Total Debt to Enterprise Value

N/A

PROFITABILITY

Gross Margin

64.60%

Operating Margin

5.38%

Pretax Margin

-8.10%

Net Margin

-4.36%

Return on Assets

-2.90%

Return on Total Capital

2.16%

Return on Invested Capital

N/A

Balance Sheet

Book Value per share

9.57

Tangible Book value per share

7.77

Total Liabilities (Quarterly)

6.8B

Total Assets

14.1B

Total Assets

6.8B

CAPITALIZATION

Total Debt to Total Equity

N/A

Total Debt to Total Capital

N/A

Total Debt to Total Assets

39.45

Long-Term Debt to Equity

N/A

Long-Term Debt to Total Capital

N/A

EFFICIENCY

Revenue/Employee

N/A

Income Per Employeee

N/A

Receivables Turnover

N/A

Total Asset Turnover

0.37

LIQUIDITY

Current Ratio

5.89

Quick Ratio

5.89

Cash Ratio

4.76

Chart

Email newsletter

Receive the latest stock news and signals

Signal Profit/Loss

Ticker

Sector / Industry

Loading…

News

#Investor Conference #Upcoming Clinical Trial Presentation

NASDAQ, PHAR

Pharming Group to attend the following Investor Conferences in June

No Comments

May 25, 2023
02:00

EST

May 25, 2023
02:00

EST

#Investor Conference

NASDAQ, PHAR

Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

No Comments

April 26, 2023
02:00

EST

April 26, 2023
02:00

EST

#Upcoming Clinical Trial Presentation

NASDAQ, PHAR

Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023

No Comments

April 13, 2023
07:11

EST

April 13, 2023
07:11

EST

#Syndromes

NASDAQ, PHAR

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

No Comments

April 11, 2023
01:00

EST

April 11, 2023
01:00

EST

#Shareholders Meeting

NASDAQ, PHAR

Pharming Group convenes the Annual General Meeting of Shareholders 2023

No Comments

April 5, 2023
02:00

EST

April 5, 2023
02:00

EST

#Financial Data

NASDAQ, PHAR

Pharming Group announces the filing of its 2022 Annual Report and Form 20-F

No Comments

April 5, 2023
01:00

EST

April 5, 2023
01:00

EST

Email newsletter

Signal

Open Position

Close Position

Profit/Loss

Pharming Group to attend the following Investor Conferences in June

Pharming Group reports financial results for the first quarter of 2023

Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023

Notice of First Quarter 2023 Results

Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Pharming Group convenes the Annual General Meeting of Shareholders 2023

Pharming Group announces the filing of its 2022 Annual Report and Form 20-F

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Tools

Learn

Account

Company

Partnerships

Create account

Sign In

Sign In